1. Home
  2. VVPR vs ACET Comparison

VVPR vs ACET Comparison

Compare VVPR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoPower International PLC

VVPR

VivoPower International PLC

HOLD

Current Price

$2.53

Market Cap

40.2M

Sector

Utilities

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$0.54

Market Cap

93.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVPR
ACET
Founded
2014
1947
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
93.5M
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
VVPR
ACET
Price
$2.53
$0.54
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$8.50
AVG Volume (30 Days)
384.6K
1.9M
Earning Date
01-01-0001
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$61,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
281.25
N/A
52 Week Low
$0.62
$0.45
52 Week High
$8.88
$1.12

Technical Indicators

Market Signals
Indicator
VVPR
ACET
Relative Strength Index (RSI) 40.51 33.71
Support Level $2.35 $0.53
Resistance Level $2.67 $0.57
Average True Range (ATR) 0.26 0.05
MACD 0.08 0.00
Stochastic Oscillator 43.10 5.35

Price Performance

Historical Comparison
VVPR
ACET

About VVPR VivoPower International PLC

Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: